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1. Introduction 
Among the different conditions of critical illness leading to admission to an Intensive Care 
Unit (ICU), sepsis remains the leading cause of death at the non-coronary medical ICU [1]. 
Even with optimal therapy, mortality rates of severe sepsis and septic shock are about 40 to 
50% [2, 3]. Although there are numerous studies with varying methods from different 
countries, the incidence of severe sepsis is constantly approximately one out of ten 
admissions to all ICUs worldwide [4]. With millions of individuals concerned every year, 
worldwide sepsis is one of the major healthcare problems today. The proportion of severe 
sepsis, and case fatal outcomes increased during the last years [2]. It is crucial to establish 
the diagnosis sepsis as early as possible and to identify its origin, in order to initiate an 
appropriate therapy permitting to achieve the best possible outcome [5].  
Sepsis is defined as a systemic inflammatory response syndrome (SIRS) caused by an 
infection. The association with organ dysfunction or sepsis-induced hypotension is termed 
severe sepsis.  Septic shock, as a subset of severe sepsis, is characterized by sepsis-induced 
hypotension, persisting despite adequate fluid resuscitation [6]. Early differentiation 
between sepsis and SIRS is a considerable problem in the treatment of patients on ICU. Due 
to the early systemic release of inflammatory cytokines as compared with synthesis of acute-
phase-proteins, cytokines have been widely investigated for their diagnostic potential in 
predicting sepsis [7]. Nevertheless, until now the perfect biomarker for differentiation of 
sepsis and SIRS has not been found yet and ongoing research focuses on identification of 
appropriate diagnostic biomarkers for sepsis [8].  
Despite a growing number of studies, the physiopathology of sepsis is not satisfyingly 
understood. Data show that physiopathology is characterized by a large number of pro- and 
anti-inflammatory cytokines and mediators of inflammation with complex interactions [9]. 
For instance, the application of a single bolus i.v. infusion of endotoxin to a healthy 
individual leads to the expression of 3147 genes, (> 10% of the human genome) [10]. These 
mediators and cytokines lead to endothelial dysfunction and activation of inflammatory and 
coagulation pathways as reaction to the invasion of a pathogen [11]. In order to reduce the 
sepsis-related high mortality, a better understanding of common pathogenic mechanisms of 
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2. Obesity in critical disease 
At present, obesity is regarded as a low-grade proinflammatory state with oxidative stress 
caused by glucose and macronutrient intake. In this setting various proinflammatory 
cytokines and acute phase reactants are induced, e.g. TNF-α and IL-6, which are mainly 
derived from the macrophages as part of the white adipose tissue [11, 12]. Oxidative stress 
leads to the production of reactive oxygen species (ROS) with NADPH oxidase as major 
vascular source of ROS [13]. ROS are particularly important for endothelial dysfunction and 
can cause cellular injury [14]. For these reasons the reaction to sepsis in obese individuals is 
different than those in individuals without chronic inflammatory state [11]. 
Obesity has been suggested as a prominent risk factor for mortality in critically ill patients, 
especially in sepsis [15, 16]. Singer et al. hypothesized that continuous low-grade chronic 
inflammation primes blood and endothelial cells to reply more rapidly to any additional 
inflammatory stimulus, such as sepsis [17]. However, recent publications on critical disease, 
only reported an influence of obesity on morbidity, but not on mortality [18, 19]. This means 
that obese and very obese patients acquired more frequently ICU-associated infections and 
had a longer length-of-stay, but there was no evidence for a higher 60-day in-hospital 
mortality compared with normal weighted patients in the study of Sakr et al. [19] .  
3. Hyperglycemia and insulin resistance in critical disease 
As in obesity, hyperglycemia, impaired glucose tolerance and insulin resistance are common 
findings in critically ill patients after surgery or with sepsis [20]. This feature has also been 
termed “diabetes of injury” [21, 22]. Hyperglycemia in hospitalized patients is known to 
lead to various adverse effects (e.g. fluid imbalance, alterations of immune function and 
inflammation), which are commonly improved by glucose control [23] (Table). 
 
Adverse effects of Acute Hyperglycemia 
 
Blood-flow abnormalities 




Proinflammatory gene expression 
Immune dysfunction 
Impairment of complement activity 
Inhibition of opsonization 
Catabolism 
Table 1. Adverse effects of Acute Hyperglycemia in critical illness (modified from [23]) 
In case of critical disease or trauma hepatic gluconeogenesis is increasing despite 
hyperglycemia and high insulin levels, whereas insulin-dependent glucose uptake in 
skeletal muscle and heart is impaired. In critically ill patients the overall glucose-uptake is 
elevated but mainly in tissues which do not depend on insulin for glucose uptake [24]. 
Hyperglycemia in critically ill patients has been related to mediators of stress, but there is 
growing evidence for causative defects in glucose metabolism [25] (Fig.1). Moreover, 
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proinflammatory cytokines can affect glucose metabolism by changing insulin receptor 
signaling and by boosting counterregulatory hormone secretion [21, 26]. Likely, 
adipocytokines link hyperglycemia and insulin resistance to inflammation in sepsis. 
 
 
Fig. 1. Etiology of acute hyperglycemia. Acute stress response is characterized by complex 
interactions of counter-regulatory hormones, cytokines and insulin sensitivity (modified 
from [23]). 
In 2001 a milestone study from van den Berghe et al. showed that tight control of 
hyperglycemia during critical illness in a cohort of cardiac surgery patients significantly 
improved outcome in terms of morbidity and mortality. Adjustment of hyperglycemia 
resulted in less severe nosocomial infections, renal and hepatic dysfunction, critical illness 
polyneuropathy, muscle weakness, and anemia [27, 28]. Increasing hyperglycemia 
paralleled increase in rates of mortality in critical illness [27]. Nevertheless, consecutive 
studies in medical ICU patients demonstrated higher mortality for intensive insulin therapy, 
potentially due to severe hypoglycemia [29]. Therefore, control of hyperglycemia by insulin 
therapy in a moderate range of blood glucose levels of 140-180 mg/dL is at present part of 
standard therapy in critically ill patients.  
4. Adipose tissue as a hormonally active organ 
Historically, adipose tissue was solely considered to store excess energy. Most recent data 
emphasize the role of adipose tissue as a hormonally active system, influencing 
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inflammation, metabolism, body weight, and lipid and glucose metabolism [30]. Proteins 
mainly secreted by adipocytes are called adipokines [11]. Matsuzawa and colleagues 
reported that approximately 30% of all genes expressed in visceral fat encode secretory 
proteins [31]. An increasing number of soluble mediators (“adipocytokines”) mainly derived 
from adipocytes itself or other cell types from adipose tissue (e.g. stromavascular fraction, 
adipose precursor cells and macrophages in the adipose tissue) have been identified. 
Adipocytokines are important mediators linking chronic inflammatory conditions to 























Fig. 2. Secretion of adipocytokines and ‘classic’ inflammatory cytokines by white adipose 
tissue. Although regarded as an adipokine resistin is in humans mainly derived from 
macrophages. TNF, tumor necrosis factor; IL, interleukin; NF, nuclear factor (modified from 
[11]). 
Potentially relevant factors released from fat tissue include hormones, adipocytokines, 
chemokines, growth factors, transcription factors, enzymes and participants of the 
coagulation cascade [33]. Many of these factors signal to organs of metabolic importance and 
the immune system and thus contribute to the phenomenon of insulin resistance [30] as 
proved for TNF-α and IL-6 [34, 35]. A recent study demonstrated similar high adipocytokine 
profiles in septic patients as well as in morbidly obese [36]. Most validated data are available 
for Interleukins-1,-6,-8 and -10, TNF-α, Resistin, Adiponectin, Leptin, Leptin-Rezeptor, 
RBP4, Osteopontin, Visfatin, Omentin, Adipsin, Sfrp5, Adipophilin and VASPIN (visceral 
adipose-tissue-derived serine protease inhibitor).  
In critically ill patients adipocytokines seem to be involved in the regulation of 
inflammation and metabolism and by this directly influence the clinical outcome of ICU 
patients. For critical illness, especially severe sepsis and septic shock, most valid data are 
available for resistin, leptin, leptin-receptor, and adiponectin.  
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Up to now, resistin is the most widely studied adipocytokine in critical illness. Human 
resistin is mainly derived from macrophages and neutrophils as recently reported [37] and 
not from adipocytes (like in mice [38]) and has been implicated in glucose metabolism and 
insulin sensitivity. It is named for mediating resistance to insulin through the exacerbation 
of the adipose tissue inflammation in humans [39]. In a knock-out mouse model it has been 
demonstrated that the lack of resistin protects against diet-induced insulin resistance and 
type 2 diabetes mellitus [40].  
Elevated resistin serum levels have been found in critically ill patients with significantly 
higher concentrations in sepsis than in non-sepsis patients and peak values in septic shock 
[37, 41]. Likely, resistin seems to act as an acute-phase protein and might be part of the 
systemic inflammatory response, as it has been correlated to IL-6, IL-10, TNF-α, C-reactive 
protein and procalcitonin [42].  
Data concerning the correlation between resistin, obesity, insulin resistance, hyperglycemia 
and diabetes mellitus are controversially discussed at present. Several studies found a 
positive correlation between resistin serum levels and hyperinsulinemia, hyperglycemia and 
insulin resistance in patients who suffer from obesity and type 2 diabetes [43, 44], but these 
findings could not be confirmed in other studies [45, 46]. Interestingly, resistin levels have 
been recently found to be independent of pre-existing diabetes mellitus or body-mass index 
(BMI) in critically ill, especially in septic patients [41, 42].  
Resistin serum levels have been correlated to renal and liver functions [47, 48], implicating 
renal and hepatic elimination or degradation of resistin. Resistin is considered as a part of 
the systemic inflammatory response from adipocytes, but in the critical illness response, 
resistin seems to be mainly derived from macrophages and not from adipocytes [42]. 
For critically ill, non-septic patients, high resistin serum concentrations have been identified 
as an adverse prognostic indicator for the ICU- as well as overall survival. Potentially, high 
resistin levels could indicate an excess of inflammatory reaction that might be of 
considerable harm, even in the absence of infection [42]. 
6. Leptin and leptin-receptor 
Since its identification in 1994 leptin has been known for its role in controlling body weight 
and food intake through hypothalamic pathways [49, 50]. The name leptin derived from the 
Greek language, as the word leptos means thin [51]. In mouse models, deficiency of leptin or 
leptin-receptor resulted in a hyperphagic, morbidly obese, and lethargic phenotype with 
significantly reduced macrophage phagocytic activity [52-54]. Circulating leptin levels 
directly reflect adipose tissue mass in non-critically ill subjects [55]. The same result applies 
in critical disease, in which leptin has also been found to closely correlate with adipose 
tissue mass; moreover, an inverse association between circulating leptin-receptor and the 
BMI in critically ill patients has been reported [56].  
Little is known about the mechanisms of leptin expression. It is secreted not only from white 
adipocytes, but also from placenta and stomach [57]. In not critically ill individuals leptin 
serum concentrations correlate with impaired insulin sensitivity, increased inflammatory 
markers, and coronary artery disease [58]. Various central and peripheral effects of leptin 
via leptin-receptors in brain and leptin-receptors in pancreas, liver, adipose tissue, and in 
the immune system, especially in human peripheral blood mononuclear cells, have been 
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described [59]. Therefore, leptin is not only involved in control of body weight and energy 
expenditure, but also in glucose homeostasis and immunoregulation. Leptin is able to 
modulate the immune response by proliferation and activation of the mononuclear cells. 
Moreover, it activates the production of proinflammatory cytokines in cultured monocytes, 
protects monocytes against apoptosis and influences RNA metabolism. The leptin-receptor 
itself is similar to members of the class I cytokine family and exists in six isoforms [60]. 
Leptin is regarded as a proinflammatory cytokine itself [61], whose action in the central 
nervous system is necessary for an adequate systemic immune response [62]. 
In animal and human studies administration of endotoxin and TNF-α as inducers of severe 
systemic inflammation resulted in significant elevation of serum leptin levels [63].  Yousef 
and colleagues also reported increased values for IL-6, CRP, TNF-α and leptin at admission 
to ICU, with leptin threshold values of 38 µg/l for distinguishing between SIRS and sepsis 
[7]. Controversially, among other studies, a study from Denmark revealed low leptin levels - 
and also low adiponectin and RBP4 levels - at admission to the ICU, possibly due to an 
acute stress response [64]. The absence of increasing leptin levels in these studies may be 
due to the short duration of the experiments, given that a delay is needed to observe an 
increase of leptin following a LPS-stimulation [65]. Another study in critically ill patients, 
including septic and non-septic groups didn’t report differences in leptin and leptin-
receptor serum concentrations as compared with healthy controls [56].  
Besides the suggested potential role as a diagnostic parameter leptin and leptin-receptor 
seem to have a prognostic impact, as high leptin-receptor serum concentrations at admission 
to ICU have been identified as an adverse prognostic indicator for survival [56]. Bornstein 
and colleagues noticed earlier that low levels of leptin might indicate a poor prognosis in 
septic patients [66]. Other studies had similar findings with exogenous leptin administration 
as a protective factor in leptin-deficient mice [67, 68]. These results are in conflict with 
observations from other investigators. Shapiro et al. reported a decrease in survival rates 
after application of exogenous leptin in murine sepsis models, whereas leptin-receptor 
deficient mice showed a better outcome with higher survival rates [60].  
Despite the strong evidence that leptin takes part in the cell-mediated immunity response 
and in cytokine crosstalk [69] additional studies for clearing the role of leptin and its 
receptors in sepsis and SIRS are warranted. 
7. Adiponectin 
Adiponectin is the most abundant adipocytokine in humans with high serum 
concentrations, normally accounting for about 0.01% of total plasma protein [70]. There are 
three different molecular forms of circulating adiponectin [30]. It is exclusively secreted by 
adipocytes with higher serum concentration in females [71]. Interestingly, despite sole 
adipocytic origin, adiponectin has been found to be inversely correlated to the BMI in 
healthy individuals and in critically ill patients as well [72]. Until now, this so called 
“adiponectin paradox” – exclusive synthesis in adipocytes but low adiponectin levels in 
obesity - has not been solved yet [73]. Secretion of adiponectin is boosted several folds by 
insulin [70], but interestingly in type 2 diabetes - as in obesity - adiponectin serum 
concentrations are reduced [74]. Reduced adiponectin levels and an association with pre-
existing diabetes mellitus have been reported in critically ill patients as well [72].  
Adiponectin has been found as an anti-atherogenic agent with positive correlation to high-
density lipoprotein cholesterol and inverse correlations to low-density lipoprotein 
cholesterol, triglycerides, insulin resistance, and diastolic blood pressure. Moreover, 
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adiponectin seems to exert direct anti-atherogenic effects on the endothelial cells [75]. 
Studies in rodents also demonstrated protective functions of adiponectin in obesity and 
insulin resistance [76]. In a study with nondiabetic, but obese patients with varying degrees 
of insulin resistance, the presence of adiponectin resulted in an increase of insulin-
sensitivity. Concomitantly to higher adiponectin serum concentrations in lean individuals, 
serum levels of TNF-α are decreased [74]. As TNF-α is presently known for its implication in 
insulin resistance, reduced serum concentrations might affect higher insulin sensitivity as 
well [77]. 
Additionally, adiponectin seems to have anti-inflammatory functions in animal models of 
sepsis. It has been reported as a potent inhibitor of cytokine production in porcine 
macrophages [78]. Furthermore, adiponectin-knockout mice had significantly higher mortality 
rates and serum levels of inflammatory markers in polymicrobial sepsis [79]. In a study of 
Teoh and colleagues the administration of adiponectin to adiponectin-knockout mice led to an 
improved outcome in experimentally generated sepsis. As concluded by the authors, low 
adiponectin levels potentially link obesity and the (discussed) worse outcome of obese patients 
in sepsis [80]. Glucocorticoids, inflammation, and oxidative stress – commonly associated with 
critical disease – are known for reducing adiponectin synthesis [81]. Matching these facts, 
some studies reported low adiponectin levels in patients with critical disease of pulmonary 
origin and also in rats with sepsis (without analyzing the impact of the measured low values 
on mortality or outcome) [64, 82]. Nevertheless, there are conflicting data concerning the role 
of adiponectin in critical illness. In a large monocenter clinical study there was no difference in 
adiponectin serum levels in critically ill patients compared to healthy controls and furthermore 
no difference between septic and non septic patients. In the same study low adiponectin serum 
concentrations at admission to ICU have been found as a positive prognostic indicator for ICU 
and overall survival in contrast to the above mentioned theory of low adiponectin levels 
worsening the outcome of critically ill patients [72].  
Interestingly, no correlation of adiponectin with cytokines or mediators of inflammation 
have been reported in critically ill patients [64, 72]. The mechanisms of adiponectin excretion 
and biodegradation in critical disease are presently unclear. Due to a reported correlation 
between adiponectin levels and markers of cholestasis and cystatin C as a marker of renal 
function, hepatic and renal elimination have been discussed in critically ill patients [72]. 
Other studies in non-ICU patients with liver cirrhosis, animal models and uremic patients 
confirm the theory of partially biliary and renal excretion of adiponectin [83, 84]. Yuan et al. 
reported a direct suppression of adiponectin gene expression by C-reactive protein in a 
concentration- and time-dependent manner [85], which might be an important finding for 
understanding adiponectin in critical disease, especially in sepsis, in which extremely high 
CRP levels are frequently found. 
As a result of the entirety of conflicting data, up to now it remains unclear whether 
circulating adiponectin is pathogenetically involved in mechanisms of critical disease 
leading to higher mortality rates. Maybe it is an epiphenomenon of variables such as 
adiposity, yet unknown functions of adipose tissue or metabolic alterations in critical illness 
[72]. 
8. Retinol binding protein 4 (RBP4)  
Retinol binding protein 4 is secreted by adipose tissue and liver. Although it is named an 
adipocytokine for its derivation of adipocytes, the main source of RBP4 in humans is the 
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liver [86]. Besides serving as a transport protein for vitamin A (retinol), RBP4 has been 
implicated in the development of insulin resistance in rodent models and in humans [87, 
88]. Von Eynatten et al. found elevated gene expression for RBP4 in the adipose tissue, but 
not in the liver of insulin-resistant mice, whereas the application of RBP4 to other mice led 
to insulin resistance [87]. Another study demonstrated down-regulation of the insulin-
responsive glucose-transporter GLUT4 in adipocytes in obesity, resulting in increased 
secretion of RBP4 by a yet unknown regulatory mechanism [88]. RBP4 has been identified as 
a marker of insulin resistance in individuals with various clinical presentations, but not yet 
manifested diabetes mellitus. The strong correlation to insulin resistance in case of obesity, 
impaired glucose tolerance, type 2 diabetes and even in lean subjects seems to be more 
specific than the correlation of other adipocytokines like leptin and adiponectin to insulin 
resistance [89].  
As a consequence of its main derivation from the liver, RBP4 serum levels are reduced in 
case of chronic and acute liver diseases or dysfunction [86, 90]. But also renal function seems 
to be important for the RBP4 metabolism with increasing levels in case of impaired renal 
function [91]. 
In critical disease RBP4 serum levels have been found decreased compared to healthy 
controls, independent of the origin of critical illness [64, 92]. During the course of disease, 
serum levels normalized with resolving critical illness [64]. Langouche and colleagues 
hypothesized that reduced synthesis or increased removal might be the reason for the 
decreased serum levels. In sepsis, capillary leakage has been considered as a possible 
mechanism for reducing the levels of adipocytokines in general [64]. As shown in another 
study the decrease in serum concentrations of RBP4 is independent of the origin of critical 
illness. There was no difference between concentrations in septic and non-septic patients 
requiring intensive care medicine, so capillary leakage as a well-known problem in sepsis 
seems not to be the main reason [92]. Instead, a strong correlation between liver and kidney 
function and serum RBP4 concentrations was found, reflecting the above mentioned relation 
of RBP4 to liver and kidney function observed in not critically ill patients [92]. As RBP4 
levels were inversely correlated with markers of inflammation, RBP4 seems potentially to be 
a member of the negative acute-phase reactants described by Richie et al. [93], what might 
be another explanation for decreased levels in critical disease [92]. At present, no association 
between RBP4 and other adipokines like adiponectin and resistin has been reported, 
suggesting that the adipose tissue does not contribute to a great extent to serum RBP4 
concentrations in critical disease [92].  
Recently, despite a missing association of RBP4 with preexisting diabetes mellitus or 
obesity, a study reported a correlation with C-peptide levels, reflecting endogenous insulin 
production, and with insulin resistance (HOMA index) [92]. The hypothesis of RBP4 
interaction in glucose metabolism is supported by a recent finding, that during intensive 
insulin therapy the raise of RBP4 levels in the course of critical illness is blunted [64]. 
Importantly, high serum concentrations of RBP4 at admission to the ICU have been 
identified as a positive predictor of ICU-survival [92]. Maybe this is due to the fact that 
higher RBP4 levels just represent preserved liver function and are not pathogenetically 
involved in the course of critical disease, as liver function itself is clearly linked to survival 
rates in critical disease [94]. Further studies are needed to definitely clarify the regulatory 
pathways of RBP4, its role in the pathogenesis of critical illness, and its significance as a 
potential novel biomarker for ICU patients.  
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Initially known as Pre-B-cell colony-enhancing factor (PBEF) this recently described 
adipocytokine was found in high concentrations in visceral fat, therefore renamed visfatin 
[95]. The third name for this eclectic protein is Nampt (nicotinamide 
phosphoribosyltransferase) [96]. Interestingly, visfatin has a unique structure without 
homology to other known proteins [96]. The number of names already indicates the divers 
properties exerted by this protein.  
As Nampt, this protein acts intracellular as the rate-limiting part of the NAD (nicotinamide 
adenine dinucleotide) production in mice [97]. NAD is an essential cofactor in numerous 
fundamental intracellular processes [98]. Moreover Kitani et al. proposed a role for PBEF in 
cell cycle regulation because of its varying intracellular distribution due to the growth phase 
of the cell [99]. 
As characteristic for adipocytokines visfatin is involved in the glucose metabolism. By binding 
to the insulin-receptor it shows insulin-mimetic effects in mice and cultured cells [100]. In 
question of reproducibility of these effects of visfatin, this publication had to be retracted 
recently [101], but Xie et al. demonstrated an insulin-like effect of visfatin on cultured 
osteoblasts [102]. Furthermore, other authors reported a correlation between visfatin serum 
levels and obesity, diabetes mellitus, and visceral fat mass [103-105]. Therefore, visfatin seems 
to be involved in a number of metabolic processes, but the definite role remains to be clarified. 
Initially PBEF was discovered by Samal et al. (1994) as a mediator of maturation of B-cells 
precursors, secreted by activated lymphocytes in bone marrow stromal cells. Its gene was 
found mainly transcribed in human bone marrow, liver tissue, and muscle [106]. Even 
though the characteristic signal peptide required for extracellular secretion of mature 
protein is missing, PBEF shows other properties which allow allocation of it to the class of 
cytokines [106]. PBEF has been found as an inhibitor of apoptosis of neutrophils in 
experimental inflammation and clinical sepsis by Jia et al. [107]. The excess of neutrophils in 
sepsis accounts for inflammatory tissue damage, e.g. for respiratory distress syndromes as 
often observed in sepsis [108]. The prolonged survival of neutrophils in sepsis due to 
inhibition of apoptosis mediated by PBEF even amplifies these destructive effects [107]. 
Furthermore increased PBEF was found in swollen or infected human fetal membranes 
indicating cytokine functions [109]. It exerts chemotactic activity and up-regulates the serum 
levels of other pro-inflammatory cytokines [110]. Garcia and Vinasco demonstrated a crucial 
role for PBEF in acute lung injury (ALI), which is usually caused by sepsis [111]. In these 
critical ill patients they found elevated concentrations of PBEF in bronchoalveolar lavage 
and serum. They identified two single nucleotide polymorphisms in the PBEF promoter, 
which seems to enhance the susceptibility for the development of ALI in septic patients.  
Although the role of PBEF as a cytokine is incompletely understood today, this protein 
seems to have a magnitude of properties contributing to the complex mechanisms 
accounting for the course of critical disease. Not at least this is underlined by the fact that 
PBEF is highly conserved through evolution as it could be identified in bacteria [112], 
invertebrate sponges [113], fishes [114], chickens and mammals [115]. 
10. Adipsin 
When adipsin was initially identified in 1983, this was the first evidence for the potential 
role of adipose tissue in regulation of immune system biology [116]. Spiegelman and 
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colleagues discovered adipsin mRNA in cultured mouse adipocyte cell lines [117]. Just a 
short time after its identification the similarity between the novel serin protease adipsin in 
mice and human complement factor D was shown [118]. Factor D is a serin protease 
accounting for the activation of the alternative pathway of complement activation. It 
constitutes the initial obligatory, rate-limiting catalytic activity of this activation by cleaving 
complement factor B when B is complexed with an activated form of complement 
component C3 [119]. The complement system is the key in innate immunity with important 
properties in enhancing adaptive immunity and in the clearance of bacteria and apoptotic 
cells [120]. In dissimilarity to mouse adipsin, which is only expressed by adipose tissue, 
human complement factor D it mainly derived from macrophages and monocytes [121]. So 
the potential involvement of this adipocytokine in critical disease seems obvious. Adipsin-
deficiency abolishes alternative-pathway dependent complement activation, in case of 
infection with Neisseria meningitidis leading to an increased susceptibility for invasive 
meningococcal disease [122, 123].  
Adipsin also seems to play an important role in energy balance as it has been found to be 
decreased in fat from genetically obese and diabetic mice in comparison to normal lean mice 
and also in serum levels of varying animal models in obesity [124, 125]. Its serum 
concentrations decline during infusion of glucose which results in a hyperglycemic and 
hyperinsulinemic state [124]. Interestingly, the serum adipsin concentrations are reduced in 
case of genetically and chemical induced obesity, whereas in the state of adiposity resulting 
from pure overfeeding there is no change leading to the conclusion that adipsin could be a 
marker for distinguishing between obesity caused by metabolic disorders or caused just by 
overfeeding [124].  
11. Conclusion 
Overall, adipocytokines in critical illness seem to fulfill various functions which are at 
present not satisfyingly understood. The interaction of metabolic and inflammatory 
mediators has been found of prognostic impact in these patients. More and more functions 
of adipocytokines and their interaction in insulin resistance, obesity and immune reactions 
have been unraveled by an increasing number of clinical and animal studies. Nevertheless, 
further future research is crucial to understand the complex effects of adipocytokines and 
their role as a link between inflammation and metabolism in critical disease. 
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